Compared side by side
Tirzepatide vs enicepatide: how they differ
The short answer
Both are weekly shots that switch on the GLP-1 and GIP receptors; enicepatide, from Roche, is built to trigger the receptors’ main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell, with the aim of keeping them responsive. Tirzepatide is FDA-approved, as Mounjaro and Zepbound; enicepatide has been in phase 3 since March 2026 and isn’t approved anywhere. Tirzepatide’s 15 mg produced up to 22.5% weight loss at 72 weeks (SURMOUNT-1), and in its 48-week phase 2 obesity trial enicepatide’s top 24 mg dose took off about 22.5% more weight than placebo.
Side by side
| Compared | Tirzepatide | Enicepatide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Mounjaro, Zepbound, LY3298176 | CT-388, CT388, RO7795068 |
| What it is | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). | A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. |
| How it works | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. | Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, tirzepatide's pair, with a twist: it is built to trigger the receptors' main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell. The idea is that receptors stay on the surface and keep responding, so the effect lasts. Its half-life in people is about 5 to 6 days. Developed by Carmot Therapeutics and now Roche, in phase 3 since March 2026. |
| Commonly reported | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). | In trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere. |
| Studied range | FDA label: 2.5–15 mg, starting dose 2.5 mg. | Research range: 4–24 mg, starting dose 2 mg. Studied in research — not a recommendation. |
| How often | Weekly | Weekly |
| Half-life | ~5 days (FDA label) | ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026) |
| Route | SubQ injection | SubQ injection |
| Typical run | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. | Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue | Nausea, constipation, diarrhea, vomiting |
- Category
- TirzepatideMetabolic & GLP-1
- EnicepatideMetabolic & GLP-1
- Also known as
- TirzepatideMounjaro, Zepbound, LY3298176
- EnicepatideCT-388, CT388, RO7795068
- What it is
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- EnicepatideA weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals.
- How it works
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- EnicepatideOnce-weekly peptide that switches on both the GLP-1 and the GIP receptors, tirzepatide's pair, with a twist: it is built to trigger the receptors' main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell. The idea is that receptors stay on the surface and keep responding, so the effect lasts. Its half-life in people is about 5 to 6 days. Developed by Carmot Therapeutics and now Roche, in phase 3 since March 2026.
- Commonly reported
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- EnicepatideIn trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.
- Studied range
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- EnicepatideResearch range: 4–24 mg, starting dose 2 mg. Studied in research — not a recommendation.
- How often
- TirzepatideWeekly
- EnicepatideWeekly
- Half-life
- Tirzepatide~5 days (FDA label)
- Enicepatide~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026)
- Route
- TirzepatideSubQ injection
- EnicepatideSubQ injection
- Typical run
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- EnicepatideUsed continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it.
- Evidence
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- EnicepatideModerate: animal studies + some human data
- Common side effects
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
- EnicepatideNausea, constipation, diarrhea, vomiting
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Enicepatide
- Day 1–28 · 2 mg Two milligrams, the first step
- Day 29–112 · 8 mg Through the middle steps
- Day 85–336 With type 2 diabetes
- Day 113–336 · 24 mg The top dose tested
- Day 337+ A long-term medicine, not a course
Questions people ask
How long do tirzepatide and enicepatide last?
The half-life of tirzepatide is ~5 days (FDA label). The half-life of enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).
How often are tirzepatide and enicepatide taken?
Tirzepatide: weekly. Route: SubQ injection. Enicepatide: weekly. Route: SubQ injection.
How are tirzepatide and enicepatide dosed in research?
The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose. The research range for enicepatide is 4–24 mg, with a 2 mg starting dose. Studied in research — not a recommendation.
What are the common side effects of tirzepatide and enicepatide?
For tirzepatide, the library lists: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue. For enicepatide: nausea, constipation, diarrhea, vomiting.